BNGO/ News und Infos Forum: Community User: Ray7

https://www.tipranks.com/news/article/bionano-ogm-system-on-track-for-further-adoption?utm_source=stck.pro&utm_medium=referral

Alles im Auge behalten.. Stärken sowie Schwächen

https://finance.yahoo.com/news/bionano-not-genomics-stock-bet-190445660.html?guccounter=1

Maxim Group Adjusts Bionano Genomics Price Target to $6 From $12, Maintains Buy Rating MT Newswires·2/2/2022, 2:38:37 PM

http://crweworld.com/article/news-provided-by-globenewswire/2275659/bionano-genomics-announces-uk-footprint-expansion-with-adoption-of-its-saphyr-system-for-optical-genome-mapping-in-two-genetic-laboratory-hubs-within-the-united-kingdoms-national-health-service

Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data today announced the publication of a study that evaluated the performance and clinical utility of combining OGM and a 523-gene next-generation sequencing (NGS) panel for comprehensive evaluation of myeloid tumors and compared it to standard cytogenetic methods (karyotyping and fluorescence in situ hybridization (FISH) and a 54-gene NGS panel. This study reported superior performance as compared to standard methods and marks two major developments in the ongoing evaluation of combined OGM and NGS workflows. This study is the first published example where the combination of workflows was applied in the context of myeloid cancers, and demonstrated higher sensitivity, resolution, accuracy and ability to reveal cryptic and clinically relevant novel variants in myeloid cancers as compared to standard methods. This is also the first study to publish results using the simultaneous visualization and interpretation of sequence and copy number variants (CNVs) in the BioDiscovery NxClinical software v6.1 from OGM and NGS data. “This research demonstrated that the combination of OGM and a 523-gene NGS panel is superior to standard methods and cost effective for comprehensive genomic profiling of myeloid cancers. When compared to whole-genome sequencing approaches that others have suggested, I believe it has better detection performance at a lower cost,” commented Dr. Ravindra Kolhe, Associate Dean for Translational Research at Medical College of Georgia and Director of the Georgia Esoteric and Molecular Laboratory at Augusta University. “With new tools to simultaneously visualize sequence variants and structural variants, we are well-positioned to move this approach into routine use, which we expect will deepen our understanding of hematological malignancies.” The research, led by Dr. Kolhe’s team at the Medical College of Georgia/Augusta University, evaluated the use of OGM and a 523-gene NGS panel for genomic profiling of 15 myeloid tumors and compared results to karyotyping, FISH, and a 54-gene NGS panel. Results demonstrated 100% analytical concordance of OGM and the 523-gene NGS panel for variants found with traditional methods. In addition, OGM better characterized structural variants (SVs) previously reported by karyotyping in five cases and identified additional translocations and 11 CNVs. “We believe this publication demonstrates the advantages of performing OGM side-by-side with NGS, for a combined workflow that can provide a more comprehensive, accurate detection of genetic variants at a cost and complexity that is practical for laboratories,” commented Erik Holmlin, PhD, President and Chief Executive Officer of Bionano. “With NxClinical software that allows for combined visualization of sequence and structural variants, we believe we have provided a tool that can make a combined OGM and NGS approach simple, scalable and superior to traditional methods.”

https://ir.bionanogenomics.com/news-releases/news-release-details/bionano-genomics-announces-publication-first-study-combine-ogm

BIONANO GENOMICS ANNOUNCES PUBLICATION OF THE FIRST STUDY TO COMBINE OGM AND NGS TO EVALUATE MYELOID CANCERS - Whole genome analysis by OGM together with analysis using a 523-gene NGS panel can perform better and cost less than analysis with karyotyping, FISH, and a 54-gene NGS panel - First study to publish results using NxClinical software for simultaneous visualization and interpretation of sequence and copy number variants from NGS and OGM data -->

Bionano Genomics Announces Publication of First Study to Combine OGM and NGS to Evaluate amyloid Cancers Whole genome analysis by OGM together with analysis using a 523-gene NGS panel can perform better and cost less than analysis with karyotyping, FISH, and a 54-gene NGS panel First study to publish results using NxClinical software for simultaneous visualization and interpretation of sequence and copy number variants from NGS and OGM data SAN DIEGO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data today announced the publication of a study that evaluated the performance and clinical utility of combining OGM and a 523-gene next-generation sequencing (NGS) panel for comprehensive evaluation of myeloid tumors and compared it to https://ir.bionanogenomics.com/news-releases/news-release-details/bionano-genomics-announces-publication-first-study-combine-ogm/

Bionano Saphyr Systems sold - Bionano Genomics: A Contract Award Notice: by BELFAST HEALTH AND SOCIAL CARE TRUST Published: 18 Jan 2022 Total Amount: £300,000 (approx $406,000 USD) No other reasonable alternative exists for this procurement as this service is essential to patient care and service delivery. This is a highly specialised element of the service, this system is capable of analysing genomes of the complexity and size of the human genome providing the required diagnostic utility. https://bidstats.uk/tenders/2022/W03/767099305

Bionano Genomics Announces Record Daily Attendance for 2022 Symposium with 63% Increase Relative to Last Year Bionano Genomics Wed, January 19, 2022, 2:00 PM·7 min read In this article: BNGO 2.55% Average daily attendance of 565 in 2022 versus 346 in 2021 Over 4,000 registrants with attendees represented from 82 countries 31 oral presentations delivered across four consecutive days 37 scientific posters featuring OGM in the online exhibit hall On-demand presentations from Symposium available for remainder of 2022 SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, today announced the conclusion of Bionano’s 2022 Symposium, with record daily attendance representing a 63% increase relative to last year’s event. Bionano’s premier scientific event showcasing OGM, Symposium was held January 10-13, 2022. Symposium had over 4,000 registrants from 82 countries and featured 31 oral presentations and 37 scientific posters from genomic scientists at leading institutions, including Brigham and Women’s Hospital, MD Anderson Cancer Center, and Quest Diagnostics. During this four-day online event, presenters reported on their use of OGM and its utility for genetic disease and cancer applications. “We were impressed by the engagement at 2022 Symposium and are excited by the accomplishments of the genomic scientists from around the world who presented their data,” commented Alka Chaubey, PhD, FACMG, and Chief Medical Officer of Bionano. “Each presenter showcased how OGM can outperform legacy techniques, resolve decades-long questions in pathogenicity of genetic disease, and complement multiple sequencing-based methods. We believe the record attendance at this year’s Symposium speaks to the strong support the research community has in pushing OGM workflows forward.”

Unser CEO ;)

https://youtu.be/GxEgNYYLxNs

Mark Oldakowski, Chief Operating Officer of Bionano said, “Guided by our intimate knowledge of our customers’ needs, the progress this team has made has been spectacular. Next year, I look forward to sharing additional amazing advancements for this new imaging system we hope will delight our customers.” Prototype photos of the next single molecule imaging system for OGM will be made available on Bionano’s social media channels on December 31, 2021.